Literature DB >> 17725599

Risk factors for local and distant recurrence of hepatocellular carcinomas after local ablation therapies.

Kazuhiro Nouso1, Eiji Matsumoto, Yoshiyuki Kobayashi, Shin-Ichiro Nakamura, Hironori Tanaka, Toshiya Osawa, Hiroshi Ikeda, Yasuyuki Araki, Kohsaku Sakaguchi, Yasushi Shiratori.   

Abstract

BACKGROUND AND AIM: Hepatocellular carcinoma (HCC) recurs frequently after local ablation therapies. Recurrence following the therapies may be of two types: local recurrence and distant recurrence. The aim of the current study is to separately elucidate the predisposing factors for each recurrence.
METHODS: Among the 2141 consecutive patients with HCC who were admitted to our institute and affiliated hospital between May 1997 and April 2004, 621 patients who had undergone local ablation therapies as the initial treatment were enrolled. Correlations between the clinical backgrounds of the patients and the type of recurrence were analyzed by the Cox proportional hazard model.
RESULTS: A multivariate analysis revealed that tumor size (>30 mm; risk ratio 2.80; 95% confidence interval, 1.77-4.45; P < 0.0001), tumor number (> or =2; 1.74, 1.23-2.47, P = 0.002), and the serum alpha-fetoprotein level (>100 ng/mL; (1.62, 1.09-2.41, P = 0.014), which were classified as "tumor factors", were significant predisposing factors for the local recurrence of HCC. In contrast, a low platelet count (<100,000/microL; 1.34, 1.04-1.74, P = 0.03) and the presence of ascites (1.73, 1.16-2.57, P = 0.008), which were classified as "background factors", as well as tumor size (1.83, 1.11-3.01, P = 0.02) and tumor number (2.23, 1.72-3.00, P < 0.0001) were predisposing factors for distant recurrence.
CONCLUSION: The predisposing factors for local and distant recurrence of HCC differ and different precautions must be observed to prevent recurrence, depending on the HCC status and background liver functions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725599     DOI: 10.1111/j.1440-1746.2007.05120.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  12 in total

1.  A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.

Authors:  Yuzo Umeda; Hiroaki Matsuda; Hiroshi Sadamori; Hiroyoshi Matsukawa; Takahito Yagi; Toshiyoshi Fujiwara
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

Review 2.  Local recurrence of hepatocellular carcinoma after radiofrequency ablation.

Authors:  Wang-Jun Liao; Min Shi; Jin-Zhang Chen; Ai-Min Li
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

3.  Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.

Authors:  Hideaki Kinugasa; Kazuhiro Nouso; Yasuto Takeuchi; Tetsuya Yasunaka; Hideki Onishi; Shin-ichiro Nakamura; Hidenori Shiraha; Kenji Kuwaki; Hiroaki Hagihara; Fusao Ikeda; Yasuhiro Miyake; Akinobu Takaki; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2011-11-03       Impact factor: 7.527

Review 4.  Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis.

Authors:  Qing Pang; Kai Qu; Jian-Bin Bi; Su-Shun Liu; Jing-Yao Zhang; Si-Dong Song; Ting Lin; Xin-Sen Xu; Yong Wan; Ming-Hui Tai; Hao-Chen Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

5.  Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.

Authors:  Qing Pang; Jing-Yao Zhang; Xin-Sen Xu; Si-Dong Song; Kai Qu; Wei Chen; Yan-Yan Zhou; Run-Chen Miao; Su-Shun Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

6.  SQSTM1 Expression in Hepatocellular Carcinoma and Relation to Tumor Recurrence After Radiofrequency Ablation.

Authors:  Amr Abdel-Moety; Nahed Baddour; Perihan Salem; Hesham El-Tobgy; Assem El-Shendidi
Journal:  J Clin Exp Hepatol       Date:  2021-12-09

7.  Soluble form of CTLA-4 is a good predictor for tumor recurrence after radiofrequency ablation in hepatocellular carcinoma patients.

Authors:  Wei Teng; Wen-Juei Jeng; Wei-Ting Chen; Chen-Chun Lin; Chun-Yen Lin; Shi-Ming Lin; I-Shyan Sheen
Journal:  Cancer Med       Date:  2022-04-18       Impact factor: 4.711

8.  Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis.

Authors:  Kanehiko Suwa; Toshihito Seki; Kazunori Aoi; Masao Yamashina; Miki Murata; Noriyo Yamashiki; Akiyoshi Nishio; Masaaki Shimatani; Makoto Naganuma
Journal:  Abdom Radiol (NY)       Date:  2021-03-06

9.  Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis.

Authors:  Hao Cai; Wentao Kong; Tie Zhou; Yudong Qiu
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

10.  Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation.

Authors:  Hyun Ah Chung; Jeong-Han Kim; Young Hwang; Hong Seok Choi; Soon Young Ko; Won Hyeok Choe; So Young Kwon
Journal:  Saudi J Gastroenterol       Date:  2016 Jan-Feb       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.